Scientists weaponize Patients' own cells to fight advanced blood cancers
NCT ID NCT05544968
Summary
This early-stage trial is testing a new personalized immunotherapy for people with advanced CD30-positive blood cancers that have returned or not responded to standard treatments. Doctors take a patient's own immune cells (T-cells), arm them with special antibodies in the lab, and infuse them back to target and attack cancer cells. The main goals are to find a safe dose and see if this approach shows early signs of effectiveness in up to 42 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert & the Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.